SecBot SecBot
PRESS-RELEASE ·Filed Nov 10, 2026

IMTX

https://immatics.com/
NEUTRAL
Impact 4/10
Horizonmonths Processed6d 19h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

SUPRAME enrollment completion by year-end and H1 2027 PFS data are the key catalysts. Cash runway into Q4 2028 reduces near-term financing risk. Monitor BLA submission timing in 2027.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

IMTX drug pipeline →

IMA203

▲ Bullish Named in this press release
Impact
Phase
Phase 3
Time to market
If Phase 3 succeeds, BLA submission is planned for 2027 with a potential commercial launch in 2027-2028.
Next catalyst
None dated

What to watchThe binary catalyst is the SUPRAME Phase 3 final PFS readout in H1 2027. Positive data would validate anzu-cel for BLA submission in 2027 and could drive significant upside toward analyst targets (~$17). A negative or underwhelming result would likely hit the stock hard given its current single-asset weighting. Interim operational updates on enrollment could come at the Q3 earnings call on Nov 16, 2026.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$6.42
T+0 close · Nov 10, 2026 · via day close
Latest settled
+4.21%
T+1 · $6.69
Vs SPY
+2.89%
α at T+1
Next horizon
T+5
in 4h
  1. T+0 · Nov 10 $6.42entry
  2. T+1 · 6d ago +4.21%α +2.89% · $6.69
  3. T+4 · todayOpen
  4. T+5 · in 4h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Immatics reported Q3 2026 net loss of $86.3M (€76.0M), wider than the $57.3M loss a year ago, driven by higher R&D costs for the SUPRAME Phase 3 trial. Revenue from collaborations rose to $7.8M from $5.9M. Cash of $536.3M extends runway into Q4 2028, and the company reiterated SUPRAME enrollment completion by year-end with topline PFS data in H1 2027.

Key Financial Metrics

Revenue
$7.8M
est $12.4M · -37.1% · +32.2% YoY

Key Facts

  • Net loss of $86.3M (€76.0M) for Q3 2026 vs $57.3M loss in Q3 2025
  • Revenue from collaborations $7.8M (€6.9M) vs $5.9M in Q3 2025
  • Cash and financial assets $536.3M (€472.3M) as of Sep 30, 2026; cash reach into Q4 2028
  • SUPRAME Phase 3 enrollment on track to complete by year-end; topline PFS data expected H1 2027
  • R&D expenses $79.8M (€70.3M) vs $53.6M in Q3 2025, driven by SUPRAME trial costs
  • Net loss per ADS (basic and diluted) €0.50 for Q3 2026 vs €0.42 in Q3 2025

Financial Impact

Net loss widened by $29M YoY; cash position essentially flat after $197.5M in gross offering proceeds offset by R&D spending

net lossrevenuecash positionR&D expenses

Risk Factors

  • Phase 3 SUPRAME trial may fail to meet PFS endpoint, delaying or preventing approval
  • Net loss growing faster than revenue; cash burn rate increased significantly in Q3 2026
  • Regulatory and commercial execution risks for anzu-cel launch

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3399294

Track record

23 reports on IMTX

Performance horizon

8 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +22.12% at T+20 after the May 12, 2026 report. 9 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $6.24 Now $6.17 −1.12% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $6.55 Now $6.17 −5.73% settles Nov 23
  3. Nov 10, 20266d ago 6-K Neutral 5/10 No price data
  4. Nov 10, 20266d ago Press Release Neutral 4/10 Viewing Entry $6.42 Now $6.17 −3.89% settles Nov 17
  5. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
  6. Oct 24, 202624d ago Press Release Bullish 6/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
  7. Oct 23, 202624d ago 6-K Bullish 7/10 Entry $7.31 to $7.20 Now $6.17 −15.60% ▼ −1.50% −0.95% vs SPY
  8. Aug 27, 202611w ago Insider Buy Bullish 6/10 Entry $9.45 to $9.56 Now $6.17 −34.71% ▲ +1.16% +1.05% vs SPY
  9. Aug 26, 202611w ago 6-K Bearish 6/10 Entry $9.36 to $9.46 Now $6.17 +34.08% ▼ −1.07% −0.80% vs SPY
  10. Aug 18, 202612w ago 6-K Neutral 6/10 Entry $9.09 to $9.24 Now $6.17 −32.12% ▲ +1.65% +1.85% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026